SNPMiner Trials (Home Page)
Report for Clinical Trial NCT00931944
Developed by Shray Alag, 2020.
SNP Clinical Trial Gene
This is an open-label, multi-center study designed to extend the evaluation of the safety,
tolerability, and clinical effects of oral administration of KNS-760704 in patients with ALS.
Name: KNS-760704
Description: 150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
Type: Drug
Group Labels: 1 KNS-760704 300 mg/day
Primary Outcomes
Measure: The primary objective of the study is to extend the evaluation of long-term safety and tolerability of KNS-760704 300 mg daily. Time: 180 weeks
Secondary Outcomes
Measure: The secondary objective of the study is to evaluate the long-term effects of KNS-760704 300 mg daily on measures of clinical function. Time: 180 weeks
Purpose: Treatment
Allocation: N/A
Single Group Assignment
There is one SNP
SNPs
1 Q12H
Eligible patients will receive 1 tablet of KNS-760704 150 mg every 12 hours (Q12H) (300 mg
total daily dose) for up to 180 weeks. --- Q12H ---